Rhofade, Oxymetazoline Cream 1% for the redness of Rosacea

Rhofade is Allergan’s Oxymetazoline based topical treatment for the red face of rosacea. Rhofade is known chemically as a Selective α1-Adrenergic Receptor Agonist, and during the drug’s development was known as AGN-199201 and also V-101.

Recent Rosacea Blog Posts

Rhofade – Allergan’s oxymetazoline brand name

Allergan haven’t announced it yet, but it seems pretty clear that they are planning to use the brand name Azultro for their oxymetazoline based treatment for the erythema of rosacea. Azultro started life as V-101 when owned by Vicept Therapeutics. It was renamed as AGN-199201 after Allergan purchased Vicept. Actavis now owns Allergan. I had […]

Continue Reading

The dermatology news sheet Dermatology Times has published an item to their web site about the emerging use of oxymetazoline to treat the redness and flushing associated with rosacea. This article draws from the Nov. 2007 paper that introduced us to the possibility of treating rosacea with oxymetazoline. We also know from the Feb. 2008 […]

Continue Reading

Oxymetazoline good for 6 hours and safe for 3 months

This poster abstract is an update to the paper that was published in Archives of Dermatology in 2007 and was covered by Rosacea News as Sansrosa’s sister to enter redness race. This now expanded abstract suggests that oxymetazoline is effective for up to 6 hours after application and no side effects have been seen after […]

Continue Reading

Sansrosa’s Sister (oxymetazoline) to enter redness race

PubMed pushed out an interesting abstract in the last couple of days. A bit of digging reveals what looks to be a running mate for COL-118/Sansrosa. COL-118 and Oxymetazoline appear to be promoted by separate groups of researchers. This is good news for rosacea sufferers as it means there may well be a choice between […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.